Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL22 in Cladribine-Resistant Hairy Cell Leukemia
NCT00074048Phase 2Completed
- Sponsor
- MedImmune
- Start
- Oct 2003
- Primary completion
- Apr 2007
- Modality
- Antibody Fragments, Antibody-Drug Conjugates (ADCs), Immunotoxins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BL22 in hairy cell leukemia (HCL), sponsored by MedImmune. Primary endpoint: Response Rate. Started Oct 2003; status: completed.
02
Drugs
BL22
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT00074048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074048.